Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Notes Payables (2020 - 2025)

iBio (IBIO) has disclosed Notes Payables for 6 consecutive years, with $706000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Notes Payables rose 211.01% to $706000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $706000.0, a 211.01% increase, with the full-year FY2025 number at $766000.0, up 522.76% from a year prior.
  • Notes Payables was $706000.0 for Q3 2025 at iBio, down from $766000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $22.2 million in Q3 2022 to a low of $123000.0 in Q2 2024.
  • A 5-year average of $8.1 million and a median of $6.7 million in 2023 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: skyrocketed 3593.5% in 2022, then crashed 99.05% in 2024.
  • iBio's Notes Payables stood at $600000.0 in 2021, then skyrocketed by 2568.5% to $16.0 million in 2022, then dropped by 20.96% to $12.7 million in 2023, then plummeted by 98.13% to $237000.0 in 2024, then surged by 197.89% to $706000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Notes Payables are $706000.0 (Q3 2025), $766000.0 (Q2 2025), and $824000.0 (Q1 2025).